Expanded Access Program for Patients With Migraine

Study Title
Expanded Access Program for Patients With Migraine
Teva Identifier
TV48125-CNS-80005
ClinicalTrials.gov Identifier
NCT03539393
Study Status
No longer available
Trial Condition(s)
Migraine
Interventions
Drug: Fremanezumab

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age Range
18 Years to 70 Years
Trial Duration
01/00/1900 - 01/00/1900

Study Type

Expanded Access:Treatment IND/Protocol